PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols
about
Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate CancerPCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experiencePCA3 in the detection and management of early prostate cancer.Urinary biomarkers for prostate cancer: a review.Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?Addressing the need for repeat prostate biopsy: new technology and approaches.Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.The role of prostate cancer biomarkers in undiagnosed men.Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness.A proposal of a new nomogram for predicting upstaging in contemporary D'Amico low-risk prostate cancer patients.Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.From biomarkers to therapeutic targets-the promises and perils of long non-coding RNAs in cancer.Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.
P2860
Q26784517-DC0FC710-7498-4BBC-BD0A-DC29599444C0Q35074229-187C2F8D-7A7C-46D3-83D7-8453DFE587F9Q38090552-4F5D8A0E-2D27-4EAB-994A-35112981FCDBQ38092578-683BF08D-6885-4203-9F17-2FD57BA654FFQ38144712-D07C96C2-48E4-44F8-A2DF-41E55A4FD5F5Q38546671-DADF1FE0-2CC6-442A-83D0-F36EA1A07BDDQ38854599-DB61BD60-DE2F-4044-89C1-BB4F07C6FD73Q39140686-B101C94A-C031-478D-A540-79EB32C0CDF8Q40211476-6FD2CF26-9318-4630-B054-5C7876331137Q40706344-E564FBE1-D361-4BE8-9458-7CD0823724D7Q42659330-88968E1F-26FE-4883-9ACB-39E96961F0EBQ47287055-1EFAD227-29E6-40F6-AE1F-4C6CFB248C04Q47436741-F849D760-8CEB-4A58-9E98-019A65E8068B
P2860
PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
PCA3 molecular urine assay for ...... impact of collection protocols
@en
type
label
PCA3 molecular urine assay for ...... impact of collection protocols
@en
prefLabel
PCA3 molecular urine assay for ...... impact of collection protocols
@en
P2093
P2860
P1476
PCA3 molecular urine assay for ...... impact of collection protocols
@en
P2093
David K Ornstein
Kathryn Osann
Michael A Liss
Rosanne Santos
P2860
P2888
P304
P356
10.1007/S00345-010-0623-6
P577
2010-12-09T00:00:00Z
P5875
P6179
1000103755